tela bio inc - TELA
TELA
Close Chg Chg %
1.14 0.00 0.00%
Open Market
1.14
0.00 (0.00%)
Volume: 76.55K
Last Updated:
Dec 24, 2025, 1:00 PM EDT
Company Overview: tela bio inc - TELA
TELA Key Data
| Open $1.12 | Day Range 1.09 - 1.14 |
| 52 Week Range 0.86 - 3.10 | Market Cap $50.76M |
| Shares Outstanding 44.53M | Public Float 33.06M |
| Beta 0.87 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.89 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 171.07K |
TELA Performance
| 1 Week | 0.88% | ||
| 1 Month | -0.87% | ||
| 3 Months | -21.38% | ||
| 1 Year | -60.82% | ||
| 5 Years | -92.87% |
TELA Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
5
Full Ratings ➔
About tela bio inc - TELA
TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company was founded by Antony Koblish and Maarten Persenaire on April 17, 2012 and is headquartered in Malvern, PA.
TELA At a Glance
TELA Bio, Inc.
1 Great Valley Parkway
Malvern, Pennsylvania 19355
| Phone | 1-484-320-2930 | Revenue | 69.30M | |
| Industry | Medical Specialties | Net Income | -37,841,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 18.557% | |
| Fiscal Year-end | 12 / 2025 | Employees | 209 | |
| View SEC Filings |
TELA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.243 |
| Price to Book Ratio | 4.181 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.881 |
| Enterprise Value to Sales | 1.104 |
| Total Debt to Enterprise Value | 0.563 |
TELA Efficiency
| Revenue/Employee | 331,578.947 |
| Income Per Employee | -181,057.416 |
| Receivables Turnover | 6.863 |
| Total Asset Turnover | 0.838 |
TELA Liquidity
| Current Ratio | 5.005 |
| Quick Ratio | 4.186 |
| Cash Ratio | 3.377 |
TELA Profitability
| Gross Margin | 67.082 |
| Operating Margin | -60.166 |
| Pretax Margin | -54.812 |
| Net Margin | -54.605 |
| Return on Assets | -45.764 |
| Return on Equity | -159.872 |
| Return on Total Capital | -52.912 |
| Return on Invested Capital | -57.312 |
TELA Capital Structure
| Total Debt to Total Equity | 151.307 |
| Total Debt to Total Capital | 60.208 |
| Total Debt to Total Assets | 49.308 |
| Long-Term Debt to Equity | 149.392 |
| Long-Term Debt to Total Capital | 59.446 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Tela Bio Inc - TELA
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 29.46M | 41.42M | 58.45M | 69.30M | |
Sales Growth
| +61.77% | +40.58% | +41.13% | +18.56% | |
Cost of Goods Sold (COGS) incl D&A
| 10.65M | 14.37M | 18.34M | 22.81M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 535.00K | 1.19M | 808.00K | 1.01M | |
Depreciation
| 231.00K | 383.00K | 428.00K | 632.00K | |
Amortization of Intangibles
| 304.00K | 804.00K | 380.00K | 380.00K | |
COGS Growth
| +52.60% | +34.97% | +27.60% | +24.38% | |
Gross Income
| 18.81M | 27.04M | 40.11M | 46.49M | |
Gross Income Growth
| +67.46% | +43.75% | +48.32% | +15.90% | |
Gross Profit Margin
| +63.85% | +65.30% | +68.62% | +67.08% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 48.26M | 66.05M | 84.19M | 88.18M | |
Research & Development
| 6.74M | 8.94M | 9.62M | 8.81M | |
Other SG&A
| 41.52M | 57.11M | 74.57M | 79.37M | |
SGA Growth
| +32.20% | +36.85% | +27.46% | +4.75% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | 1.23M | - |
EBIT after Unusual Expense
| (29.45M) | (40.23M) | (44.08M) | (41.70M) | |
Non Operating Income/Expense
| (228.00K) | (10.00K) | 2.63M | 9.00M | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 3.60M | 4.05M | 5.22M | 5.29M | |
Interest Expense Growth
| +0.93% | +12.62% | +28.93% | +1.28% | |
Gross Interest Expense
| 3.60M | 4.05M | 5.22M | 5.29M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (33.28M) | (44.30M) | (46.66M) | (37.98M) | |
Pretax Income Growth
| -15.57% | -33.12% | -5.35% | +18.60% | |
Pretax Margin
| -112.94% | -106.95% | -79.83% | -54.81% | |
Income Tax
| - | - | - | (144.00K) | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (33.28M) | (44.30M) | (46.66M) | (37.84M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (33.28M) | (44.30M) | (46.66M) | (37.84M) | |
Net Income Growth
| -15.57% | -33.12% | -5.35% | +18.91% | |
Net Margin Growth
| -112.94% | -106.95% | -79.83% | -54.60% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (33.28M) | (44.30M) | (46.66M) | (37.84M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (33.28M) | (44.30M) | (46.66M) | (37.84M) | |
EPS (Basic)
| -2.2991 | -2.723 | -2.0405 | -1.3265 | |
EPS (Basic) Growth
| -3.27% | -18.44% | +25.06% | +34.99% | |
Basic Shares Outstanding
| 14.47M | 16.27M | 22.87M | 28.53M | |
EPS (Diluted)
| -2.2991 | -2.723 | -2.0405 | -1.3265 | |
EPS (Diluted) Growth
| -3.27% | -18.44% | +25.06% | +34.99% | |
Diluted Shares Outstanding
| 14.47M | 16.27M | 22.87M | 28.53M | |
EBITDA
| (28.92M) | (37.82M) | (43.27M) | (40.68M) | |
EBITDA Growth
| -16.83% | -30.79% | -14.40% | +5.97% | |
EBITDA Margin
| -98.14% | -91.31% | -74.02% | -58.71% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 4.05 | |
| Number of Ratings | 5 | Current Quarters Estimate | -0.178 | |
| FY Report Date | 12 / 2025 | Current Year's Estimate | -0.818 | |
| Last Quarter’s Earnings | -0.19 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.33 | Next Fiscal Year Estimate | -0.566 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 5 | 4 | 5 | 5 |
| Mean Estimate | -0.18 | -0.16 | -0.82 | -0.57 |
| High Estimates | -0.16 | -0.15 | -0.76 | -0.49 |
| Low Estimate | -0.19 | -0.16 | -0.84 | -0.68 |
| Coefficient of Variance | -7.32 | -3.73 | -4.27 | -12.65 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 4 | 4 | 4 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 1 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Tela Bio Inc - TELA
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Tela Bio Inc - TELA
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Feb 26, 2025 | Paul Talmo Chief Technology Officer | 124,072 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.65 per share | 328,790.80 |
| Feb 26, 2025 | Gregory Firestone Chief Commercial Officer | 75,900 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 26, 2025 | Gregory Firestone Chief Commercial Officer | 106,923 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.65 per share | 283,345.95 |
| Feb 26, 2025 | Gregory Firestone Chief Commercial Officer | 107,163 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.72 per share | 291,483.36 |
| Feb 26, 2025 | Gregory Firestone Chief Commercial Officer | 108,515 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.72 per share | 295,160.80 |
| Feb 26, 2025 | Gregory Firestone Chief Commercial Officer | 108,879 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 26, 2025 | Megan Smeykal Chief Accounting Officer | 36,927 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.65 per share | 97,856.55 |
| Feb 26, 2025 | Megan Smeykal Chief Accounting Officer | 37,466 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.72 per share | 101,907.52 |
| Feb 26, 2025 | Megan Smeykal Chief Accounting Officer | 37,889 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.72 per share | 103,058.08 |
| Feb 26, 2025 | Paul Talmo Chief Technology Officer | 56,100 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 26, 2025 | Antony Koblish Chief Executive Officer; Director | 607,897 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 26, 2025 | Paul Talmo Chief Technology Officer | 125,121 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.72 per share | 340,329.12 |
| Feb 26, 2025 | Paul Talmo Chief Technology Officer | 129,182 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 26, 2025 | Roberto E. Cuca COO and CFO | 83,800 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 26, 2025 | Roberto E. Cuca COO and CFO | 208,233 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.72 per share | 566,393.76 |
| Feb 26, 2025 | Roberto E. Cuca COO and CFO | 213,467 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 26, 2025 | Antony Koblish Chief Executive Officer; Director | 219,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 26, 2025 | Antony Koblish Chief Executive Officer; Director | 590,494 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.65 per share | 1,564,809.10 |
| Feb 26, 2025 | Antony Koblish Chief Executive Officer; Director | 596,266 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.72 per share | 1,621,843.52 |